CA3026621A1 - Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same - Google Patents

Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same Download PDF

Info

Publication number
CA3026621A1
CA3026621A1 CA3026621A CA3026621A CA3026621A1 CA 3026621 A1 CA3026621 A1 CA 3026621A1 CA 3026621 A CA3026621 A CA 3026621A CA 3026621 A CA3026621 A CA 3026621A CA 3026621 A1 CA3026621 A1 CA 3026621A1
Authority
CA
Canada
Prior art keywords
alkyl
compound according
compound
subject
independently unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3026621A
Other languages
English (en)
French (fr)
Inventor
Eric Verdin
Scott Ulrich
John Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
University of California San Diego UCSD
Ithaca College
Original Assignee
J David Gladstone Institutes
University of California San Diego UCSD
Ithaca College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes, University of California San Diego UCSD, Ithaca College filed Critical J David Gladstone Institutes
Publication of CA3026621A1 publication Critical patent/CA3026621A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA3026621A 2016-06-07 2017-06-02 Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same Pending CA3026621A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346975P 2016-06-07 2016-06-07
US62/346,975 2016-06-07
PCT/US2017/035826 WO2017213999A1 (en) 2016-06-07 2017-06-02 Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

Publications (1)

Publication Number Publication Date
CA3026621A1 true CA3026621A1 (en) 2017-12-14

Family

ID=60578899

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026621A Pending CA3026621A1 (en) 2016-06-07 2017-06-02 Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

Country Status (13)

Country Link
US (4) US10889538B2 (enExample)
EP (2) EP3465335B1 (enExample)
JP (3) JP7058610B2 (enExample)
KR (2) KR102519244B1 (enExample)
CN (2) CN109477993B (enExample)
AU (2) AU2017278099B2 (enExample)
CA (1) CA3026621A1 (enExample)
CO (1) CO2018014167A2 (enExample)
IL (2) IL263561B (enExample)
MX (2) MX2021009806A (enExample)
RU (1) RU2761829C2 (enExample)
SG (1) SG11201810765PA (enExample)
WO (1) WO2017213999A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009806A (es) 2016-06-07 2022-11-30 The J David Gladstone Inst Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
AU2018304380B2 (en) 2017-07-21 2022-12-15 Buck Institute For Research On Aging S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190248733A1 (en) * 2018-02-14 2019-08-15 Benjamin Bikman Oral supplements of fatty acid and amino acid ketone esters to improve metabolic, physical and cognitive health
WO2020147983A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von gegebenenfalls acylierten hydroxycarbonsäuren
EP3880644B1 (de) * 2019-01-17 2023-09-06 KetoLipix Therapeutics GmbH Verfahren zur herstellung von verkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
EP3880642B1 (de) 2019-01-17 2026-01-14 KetoLipix Therapeutics GmbH Verfahren zur herstellung von fettalkoholestern von hydroxycarbonsäuren
CN110372502A (zh) * 2019-07-25 2019-10-25 润泰化学（泰兴）有限公司 一种1,3-二醇的双酯化合成方法
GB201918657D0 (en) 2019-12-17 2020-01-29 Tdeltas Ltd Compounds for new use
ES2980782T3 (es) * 2020-07-13 2024-10-03 Ketolipix Therapeutics Gmbh Procedimiento para la preparación de ésteres de poliglicerol de ácidos policarboxílicos esterificados con oxobutanol
BR112023000684A2 (pt) * 2020-07-13 2023-01-31 Ioi Oleo Gmbh Método para produzir ésteres de oxobutanol de ácidos carboxílicos poliméricos
US20240228422A1 (en) * 2020-07-13 2024-07-11 Ioi Oleo Gmbh Process for preparing oxobutanol esters of polymeric carboxylic acids
CN112341542B (zh) * 2021-01-08 2021-05-14 清华大学 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用
AU2022212793A1 (en) * 2021-01-26 2023-08-10 Buck Institute For Research On Aging Use of exogenous ketone esters to induce weight loss in mammals
US12059398B2 (en) * 2022-08-26 2024-08-13 Health Via Modern Nutrition Inc. Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis
US20250009707A1 (en) 2023-06-29 2025-01-09 BOPZ Nutrition Ltd. Methods of inducing ketosis in non-human mammals

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85610C (da) 1952-01-08 1958-05-27 Unilever Nv Fremgangsmåde til udvinding af fedstoffer af vandige sæbeopløsninger.
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4263216A (en) * 1978-10-20 1981-04-21 The Procter & Gamble Company Diglyceride manufacture
IL59407A (en) * 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4436726A (en) 1980-12-15 1984-03-13 Fujisawa Pharmaceutical Co., Ltd. N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
BE1001209A3 (fr) 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5219757A (en) 1988-04-27 1993-06-15 Daicel Chemical Industries, Ltd. Production of optically active 1,3-butanediol by asymmetric assimilation or reduction of 4-hydroxy-2-butanone
JP2578658B2 (ja) * 1989-02-21 1997-02-05 チッソ株式会社 光学活性化合物及びその製造法
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
IT1240760B (it) * 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
ATE129147T1 (de) 1992-01-08 1995-11-15 Nestle Sa Kosmetische und dermatologische zusammensetzung, die dioldiester enthält.
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
DE19703471A1 (de) * 1997-01-31 1998-08-06 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern
DK1017379T3 (en) * 1997-03-17 2015-02-16 Btg Int Ltd Therapeutic compositions comprising ketone compounds and precursors thereof
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6096010A (en) 1998-02-20 2000-08-01 Becton, Dickinson And Company Repeat-dose medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
EP1052240B1 (en) * 1999-05-11 2003-03-19 Dow AgroSciences LLC Process for the preparation of substituted 3-hydroxybutyrate esters
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
AU2002211666A1 (en) * 2000-10-11 2002-04-22 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
EP1528053A1 (en) 2003-10-31 2005-05-04 Lonza Ag Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
JP2006063001A (ja) 2004-08-25 2006-03-09 Takasago Internatl Corp 光学活性β−ブチロラクトンの製造方法
CN101326172A (zh) * 2005-12-07 2008-12-17 思珀药品有限公司 茉莉酮酸酯衍生物、药物组合物及它们的使用方法
US7988883B2 (en) 2006-02-10 2011-08-02 Dupont Tate & Lyle Bio Products Company, Llc Heat transfer compositions comprising renewably-based biodegradable 1,3-propanediol
WO2008089462A2 (en) * 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes and their uses
JP5054418B2 (ja) * 2007-04-23 2012-10-24 ポーラ化成工業株式会社 クレンジング用の化粧料に好適な皮膚外用剤
CN102164884B (zh) 2008-08-21 2015-03-11 伊希斯创新有限公司 羟基丁酸酯及其医学用途
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
US9034613B2 (en) 2009-04-16 2015-05-19 Isis Innovation Limited Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US9868837B2 (en) * 2010-04-28 2018-01-16 Arkema Inc. Method of improving stability of polyurethane polyol blends containing halogenated olefin blowing agent
KR101243240B1 (ko) * 2010-07-19 2013-04-04 (주)에이씨티 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물
CN103360243B (zh) * 2012-03-31 2015-06-17 中国石油化工股份有限公司 一种1,3-二酰氧基丙烷类化合物的制备方法
CN104272147B (zh) * 2012-05-01 2015-10-21 柯尼卡美能达株式会社 相位差膜、偏振片的制造方法及液晶显示装置
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
MY180761A (en) 2013-03-19 2020-12-08 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
AU2014306149B2 (en) * 2013-08-06 2019-09-19 Imago Biosciences Inc. KDM1A inhibitors for the treatment of disease
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
MX2021009806A (es) 2016-06-07 2022-11-30 The J David Gladstone Inst Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
AU2018304380B2 (en) 2017-07-21 2022-12-15 Buck Institute For Research On Aging S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190262415A1 (en) 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis

Also Published As

Publication number Publication date
EP4585270A2 (en) 2025-07-16
CN114292190B (zh) 2025-04-11
JP7058610B2 (ja) 2022-04-22
US11608308B2 (en) 2023-03-21
BR112018075102A8 (pt) 2023-04-11
JP7479337B2 (ja) 2024-05-08
SG11201810765PA (en) 2018-12-28
IL263561B (en) 2022-04-01
AU2017278099B2 (en) 2021-03-11
US10647658B2 (en) 2020-05-12
EP3465335B1 (en) 2026-04-08
BR112018075102A2 (pt) 2019-03-26
KR102519244B1 (ko) 2023-04-06
MX2018015302A (es) 2019-08-22
RU2018143895A (ru) 2020-07-09
MX385367B (es) 2025-03-18
US10562839B2 (en) 2020-02-18
CN114292190A (zh) 2022-04-08
KR20190026747A (ko) 2019-03-13
NZ788931A (en) 2025-06-27
IL291694A (en) 2022-05-01
IL263561A (en) 2019-01-31
AU2021203726A1 (en) 2021-07-01
CN109477993A (zh) 2019-03-15
US20190359551A1 (en) 2019-11-28
MX2021009806A (es) 2022-11-30
JP2019525899A (ja) 2019-09-12
CO2018014167A2 (es) 2019-01-18
US10889538B2 (en) 2021-01-12
US20210171432A1 (en) 2021-06-10
JP2024028287A (ja) 2024-03-04
EP3465335A1 (en) 2019-04-10
JP2022020701A (ja) 2022-02-01
RU2761829C2 (ru) 2021-12-13
AU2017278099A1 (en) 2018-12-20
AU2021203726B2 (en) 2023-04-06
WO2017213999A1 (en) 2017-12-14
US20190248730A1 (en) 2019-08-15
EP4585270A3 (en) 2025-09-24
KR102638807B1 (ko) 2024-02-21
US20190382333A1 (en) 2019-12-19
CN109477993B (zh) 2023-03-28
NZ748897A (en) 2025-03-28
RU2018143895A3 (enExample) 2021-03-11
AU2021203726C1 (en) 2023-10-12
EP3465335A4 (en) 2020-03-11
KR20230006926A (ko) 2023-01-11

Similar Documents

Publication Publication Date Title
AU2021203726C1 (en) Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
CN112979743B (zh) 白桦脂酸衍生物及其应用
JP5890043B2 (ja) 抗癌活性を有する２−デオキシ単糖の新規なアセテート
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのｐｐｍｐ
US8378112B2 (en) Glycyrrhetinic acid derivative and use thereof
CA2675743A1 (en) Phenazine compounds and use thereof in autoimmune and inflammatory diseases
RU2831011C1 (ru) Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола, и композиции и способы на их основе
JPS60500288A (ja) ３−（３−置換アミノ−２−ヒドロキシプロポキシ）−４−置換−１・２・５−チアゾ−ル誘導体のエステル
BR112018075102B1 (pt) Composto, composições e usos relacionados
BR122022019936B1 (pt) Composto, formulação e uso de um composto
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
WO2016182898A1 (en) Methods of use for monomethyl fumarate and prodrugs thereof
CN119792317A (zh) 一种利布拉霉素衍生物及其在神经系统疾病中的用途
EP4069208A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220602

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250514

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250514

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260302